Table 3 Demographic and clinical characteristics according to the presence or absence of visual aura in migraine and probable migraine.

From: Prevalence and impact of visual aura in migraine and probable migraine: a population study

 

Migraine with visual aura, N = 50

Migraine without visual aura, N = 120

P value

PM with visual aura, N = 82

PM without visual aura, N = 255

P value

Age (years)

40.5 (33.8–47.5)

40.0 (31.3–45.8)

0.487

43.5 (33.0–50.0)

40.0 (30.0–49.0)

0.113

Women

32 (64.0)

97 (80.8)

0.019

46 (56.1)

161 (63.1)

0.255

HA duration in hours

12.0 (6.4–40.0)

20.0 (6.0–48.0)

0.456

0.1 (0.1–0.2)

0.1 (0.1–0.2)

0.092

Frequency

4.0 (2.0–10.0)

2.0 (1.0–4.8)

0.320

2.0 (2.0–8.0)

2.0 (0.6–4.0)

0.006

HA days per month

4.0 (2.0–10.0)

3.0 (2.0–5.0)

0.044

3.0 (2.0– 5.0)

2.0 (1.0–4.0)

0.007

Severe HA days per month

2.50 (1.0–5.0)

2.00 (1.0–3.0)

0.060

2.0 (1.0–3.0)

1.0 (1.0–2.0)

0.004

HA days with medication

3.00 (1.0–5.3)

2.00 (1.0–5.0)

0.051

2.0 (1.0–5.0)

1.0 (0.0–2.0)

 < 0.001

Severe HA intensity

21 (42.0)

58 (48.3)

0.622

0 (0.0)

11 (4.3)

0.997

Moderate-to-severe intensity

50 (100.0)

120 (100.0)

1.000

55 (67.1)

172 (67.4)

0.949

VAS score

7.0 (7.0–8.0)

7.00 (7.0–8.0)

0.327

6.0 (4.0–7.0)

6.0 (4.0–7.0)

0.604

HIT-6 score

53.0 (46.0–60.3)

50.0 (45.0–56.8)

0.046

49.5 (44.0–56.0)

50.0 (44.0–58.0)

0.509

MIDAS score

14.5 (8.8–32.3)

12.5 (5.0–27.8)

0.163

10.0 (5.0–26.3)

5.0 (2.0–12.0)

 < 0.001

Unilateral pain

22 (44.0)

69 (57.5)

0.130

60 (72.3)

181 (70.7)

0.937

Pulsating pain

34 (68.0)

73 (60.8)

0.529

53 (64.6)

196 (76.9)

0.018

Aggravation by movement

40 (80.0)

98 (81.7)

0.971

56 (68.3)

128 (50.2)

0.082

Nausea

31 (62.0)

89 (74.2)

0.520

69 (84.1)

213 (83.5)

0.967

Vomiting

24 (48.0)

58 (48.3)

0.577

43 (52.4)

89 (34.9)

0.011

Photophobia

42 (84.0)

83 (69.2)

0.038

48 (58.5)

98 (38.4)

0.001

Phonophobia

43 (86.0)

94 (78.3)

0.087

53 (64.6)

113 (44.3)

 < 0.001

WPI

5.0 (3.0–7.0)

4.0 (2.0–6.0)

0.195

5.0 (4.0–7.0)

3.0 (2.0–6.0)

0.001

FS

12.0 (10.0–15.0)

12.0 (8.0–14.0)

0.032

12.0 (9.8–13.3)

9.0 (6.0–12.0)

 < 0.001

PHQ-9 score

8.0 (7.0–9.0)

8.0 (5.0–9.0)

0.755

9.0 (6.0–10.3)

7.0 (4.0–9.0)

 < 0.001

GAD-7 score

8.0 (3.8–11.5)

5.0 (3.0–9.0)

0.085

7.0 (4.0–11.0)

4.0 (1.0–7.0)

 < 0.001

ASC-12 score

3.0 (1.0–8.0)

2.0 (0.0–4.7)

0.043

2.5 (0.0–6.0)

0.0 (0.0–3.0)

 < 0.001

BEPSI-K score

2.6 (2.0–3.2)

2.2 (1.8–3.0)

0.044

2.3 (2.0–3.0)

2.0 (1.0–2.8)

0.001

M-TOQ-6 score

20.5 (16.3–24.0)

22.0 (18.0–26.0)

0.051

21.0 (17.3–25.0)

23.0 (21.0–26.5)

0.003

  1. PM: probable migraine, HA: headache, VAS: visual analogue scale, HIT-6: Headache Impact Test-6, MIDAS: Migraine Disability Assessment, WPI: Widespread Pain Index, FS: Fibromyalgia symptom severity score, PHQ-9: Patient Health Questionnaire-9, GAD-7: Generalized Anxiety Disorder-7, ASC-12: 12-item Allodynia symptom checklist, BEPSI-K: Korean version of the Brief Encounter Psychosocial Instrument, M-TOQ-6: 6-item version of the Migraine-Treatment Optimization Questionnaire.